New to Camber’s Portfolio: Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide Tablets
According to the CDC, about 40-45% of adults in the U.S. have hypertension.
Indicated for the treatment of hypertension, Camber Pharmaceuticals has added Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide Tablets to its growing portfolio of treatment options.
Generic to Tribenzor®, Camber’s Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide Tablets are available in 30 and 90 ct bottles of:
- 20 mg/5 mg/12.5mg
- 40 mg/5 mg/12.5 mg
- 40 mg/5 mg/25 mg
- 40 mg/10 mg/12.5 mg
- 40 mg/10 mg/25 mg
Recent articles
- New to Camber’s Portfolio: Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide Tablets
- Camber Pharmaceuticals Honored as Second Merit Finalist at 2026 DIANA Awards
- Camber Launches Nitazoxanide Tablets
- Cisatracurium Besylate Injection, USP Added to Camber’s Portfolio
- Camber Welcomes Summer 2026 Intern Class
- Camber Launches 5 Generics in May






